Author： Tian Tian Yu Shuang Ma Daoxin
Publisher： Informa Healthcare
ISSN： 1472-8222
Source： Expert Opinion on Therapeutic Targets, Vol.17, Iss.2, 2013-02, pp. : 113-125
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Targeting IL-23 and Th17-Cytokines in Inflammatory Bowel Diseases
Current Pharmaceutical Design, Vol. 16, Iss. 33, 2010-11 ,pp. :
Access to resources
Recommend
Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 14, Iss. 2, 2014-06 ,pp. :
Emerging Peptide Therapeutics for Inflammatory Autoimmune Diseases
Current Pharmaceutical Design, Vol. 16, Iss. 9, 2010-03 ,pp. :
Interleukin-25: Key Regulator of Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design, Vol. 17, Iss. 34, 2011-11 ,pp. :
IL-19 as a Potential Therapeutic in Autoimmune and Inflammatory Diseases
Current Pharmaceutical Design, Vol. 17, Iss. 34, 2011-11 ,pp. :